Central Trust Company’s Editas Medicine EDIT Stock Holding History

Central Trust Company’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,000	Closed	-$8.23K	–	1364
2023 Q2	$8.23K	Hold	1,000	–	–	﹤0.01%	1049
2023 Q1	$7.25K	Hold	1,000	–	–	﹤0.01%	1076
2022 Q4	$8.87K	Buy	1,000 +700	+233%	+$7.68K	﹤0.01%	1027
2022 Q3	$4K	Hold	300	–	–	﹤0.01%	1128
2022 Q2	$4K	Hold	300	–	–	﹤0.01%	1140
2022 Q1	$6K	Hold	300	–	–	﹤0.01%	1135
2021 Q4	$8K	Hold	300	–	–	﹤0.01%	1083
2021 Q3	$12K	Hold	300	–	–	﹤0.01%	1005
2021 Q2	$17K	Hold	300	–	–	﹤0.01%	910
2021 Q1	$13K	Hold	300	–	–	﹤0.01%	894
2020 Q4	$21K	Hold	300	–	–	﹤0.01%	794
2020 Q3	$8K	Sell	300 -130	-30%	-$4.23K	﹤0.01%	881
2020 Q2	$13K	Hold	430	–	–	﹤0.01%	803
2020 Q1	$9K	Hold	430	–	–	﹤0.01%	876
2019 Q4	$13K	Hold	430	–	–	﹤0.01%	903
2019 Q3	$10K	Hold	430	–	–	﹤0.01%	900
2019 Q2	$11K	Hold	430	–	–	﹤0.01%	898
2019 Q1	$11K	Hold	430	–	–	﹤0.01%	859
2018 Q4	$10K	Buy	+430	New	+$11.7K	﹤0.01%	890

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Central Trust Company's EDIT Position: Q3 2023 in Review

Central Trust Company sold out of Editas Medicine (EDIT) in Q3 2023, closing a stake of 1,000 shares — an estimated $8.23K sold.

Central Trust Company first reported a position in EDIT in Q4 2018 and held it in 19 quarters. The position peaked at $21K in Q4 2020. 220 funds tracked by Wall St. Rank hold EDIT as of Q3 2023.

Central Trust Company reported no remaining Editas Medicine position as of Q3 2023 after selling out during the quarter.
Central Trust Company sold 1,000 Editas Medicine shares in Q3 2023, an estimated $8.23K.
Central Trust Company first reported a position in Editas Medicine in Q4 2018 and held it in 19 quarters.
Central Trust Company's Editas Medicine position peaked at $21K in Q4 2020.
220 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2023.

Based on Central Trust Company's 13F filing for Q3 2023, filed 26 Oct 2023.